首页 > 按专业查询名词 > 查询PubMed相关文献
名词信息
Pubmed相关的文献
chemotherapy of advanced and recurrent tumor相关文献:
Development of a new subclavian arterial infusion chemotherapy method for locally or recurrent advanced breast cancer using an implanted catheter-port system after redistribution of arterial tumor supply.
PMID:
Acute myeloid leukaemia.
Short NJ, Rytting ME, Cortes JE.
Lancet. 2018 Aug 18;392(10147):593-606. doi: 10.1016/S0140-6736(18)31041-9. Epub 2018 Aug 2.
PMID:30078459
Updates on targeted therapies for acute myeloid leukaemia.
Kayser S, Levis MJ.
Br J Haematol. 2022 Jan;196(2):316-328. doi: 10.1111/bjh.17746. Epub 2021 Aug 4.
PMID:34350585
A review of treatment options employed in relapsed/refractory AML.
Mohamed Jiffry MZ, Kloss R, Ahmed-Khan M, Carmona-Pires F, Okam N, Weeraddana P, Dharmaratna D, Dandwani M, Moin K.
Hematology. 2023 Dec;28(1):2196482. doi: 10.1080/16078454.2023.2196482.
PMID:37036019
The role of chemotherapy in locally advanced, metastatic and recurrent cervical cancer.
Tambaro R, Scambia G, Di Maio M, Pisano C, Barletta E, Iaffaioli VR, Pignata S.
Crit Rev Oncol Hematol. 2004 Oct;52(1):33-44. doi: 10.1016/j.critrevonc.2004.05.003.
PMID:15363465
Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease.
Burton C, Allen P, Herrera AF.
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e433502. doi: 10.1200/EDBK_433502.
PMID:38728605
Advanced gastric cancer: the value of systemic and intraperitoneal chemotherapy.
Coccolini F, Fugazzola P, Ansaloni L, Sartelli M, Cicuttin E, Leandro G, De' Angelis GL, Gaiani F, Di Mario F, Tomasoni M, Catena F.
Acta Biomed. 2018 Dec 17;89(8-S):104-109. doi: 10.23750/abm.v89i8-S.7904.
PMID:30561427
Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors.
Miljković MD, Girotra M, Abraham RR, Erlich RB.
Dig Dis Sci. 2012 Jan;57(1):9-18. doi: 10.1007/s10620-011-1854-0. Epub 2011 Sep 22.
PMID:21938486
Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S, Seraj E, Zarkavelis G, Petrakis D, Kollas A, Kafantari A, Assi A, Tatsi K, Pavlidis N, Pentheroudakis G.
Crit Rev Oncol Hematol. 2016 Dec;108:164-174. doi: 10.1016/j.critrevonc.2016.11.006. Epub 2016 Nov 15.
PMID:27931835
Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy.
Czauderna P, Lopez-Terrada D, Hiyama E, Häberle B, Malogolowkin MH, Meyers RL.
Curr Opin Pediatr. 2014 Feb;26(1):19-28. doi: 10.1097/MOP.0000000000000046.
PMID:24322718
Cholangiocarcinoma Therapeutics: An Update.
Nguyen MLT, Toan NL, Bozko M, Bui KC, Bozko P.
Curr Cancer Drug Targets. 2021;21(6):457-475. doi: 10.2174/1568009621666210204152028.
PMID:33563168
© Copyright 2021 鸿泰茂源  版权所有All Rights Reserved京ICP备11040441号-3